Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-07-18
2006-07-18
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S254070
Reexamination Certificate
active
07078526
ABSTRACT:
The invention provides novel soluble conazole crystalline forms (e.g. itraconazole, posaconazole and saperconazole) that include salts, co-crystals and related solvates useful as pharmaceuticals. The invention also provides pharmaceutical compositions comprising, and processes for making, these conazole crystalline forms. Methods of using such compositions for the treatment or prevention of systemic and local fungal, yeast, and dermatophyte infections are also provided.
REFERENCES:
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4267179 (1981-05-01), Heeres et al.
patent: 4764604 (1988-08-01), Muller
patent: 4916134 (1990-04-01), Heeres et al.
patent: 5006513 (1991-04-01), Hector et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5414997 (1995-05-01), Tailer
patent: 5474997 (1995-12-01), Gray et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5633015 (1997-05-01), Gilis et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5661151 (1997-08-01), Saksena et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5707975 (1998-01-01), Francois et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5998413 (1999-12-01), Heeres et al.
patent: 2003/0096014 (2003-05-01), Sherman
patent: 2003/0224006 (2003-12-01), Zaworotko et al.
patent: 2004/0019211 (2004-01-01), Remenar et al.
patent: 2004/0176335 (2004-09-01), Childs
patent: 0310122 (1989-04-01), None
patent: 0283992 (1992-09-01), None
patent: WO 94/16733 (1994-08-01), None
patent: WO 95/17407 (1995-06-01), None
patent: WO 98/57967 (1998-12-01), None
patent: WO 01/41536 (2001-06-01), None
patent: WO 01/51919 (2001-07-01), None
patent: WO 01/97853 (2001-12-01), None
patent: WO 02/056878 (2002-07-01), None
patent: WO 02/062318 (2002-08-01), None
patent: WO 03/074474 (2003-09-01), None
patent: WO 2003101392 (2003-12-01), None
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358-365.
Kovacs, J. et al, J. Inclusion Phenomena and Molecular recognition in Chemistry, 25, 1966, 53-56.
Desiraju, Gautam R., Nature 412, 397-400 (2001).
Gavezzotti, A., Acc. Chem. Res., 1994, 27, 309-314.
Aronhime, Judith, “Crystalline forms of pharmaceuticals and characterization thereof”, oral presentation, USPTO, Alexandria, VA, Mar. 8, 2005.
McCrone, Walter C., “Polymorphism”, in “The Physics and Chemistry of the Organic Solid State, vol. II”, Fox, David et al eds, Interscience, New York, 1965, pp. 725-767.
Aronhime, Judith, “Crystalline Forms of Pharmaceuticals and Characterization Thereof”, oral presentation, USPTO, Alexandria, VA, Mar. 8, 2005.
Vippagunta, S. R. et al, Advanced Drug Delivery Reviews, 48, pp. 3-26, 2001.
Remenar, et al., “Crystal Engineering of Novel Cocrystals of a Triazole Drug with1,4-Dicarboxylic Acids”, Jun. 21, 2003,J. Am. Chem. Soc.,125 (28), pp. 8456-8457 (2003).
Cacciapuoti et al., Antimicrob. Ag. Chemother., 44: p. 2017 (2000).
Callaghan et al., Conazole Dev. Ind. Pharm., vol. 8, pp. 335-369 (1982).
Dannaoui et al., J. Antimicrob. Chemother., 47: pp. 333-340 (2001).
Denning et al., Eur. J. Clin. Microbiol. Infect. Dis., 9: p. 693 (1990).
Dressman et al., Pharm. Res., 15(1): pp. 11-22 (1998).
Ebert, Pharm. Tech., 1(5): pp. 44-50 (1977).
Gascon et al., Eur. J. Clin. Pharmacol., 41: pp. 573-578 (1991).
Heeres et al., J. Med. Chem, 27: pp. 894-900 (1984).
Honig et al., J. Clin. Pharmacol., 33: pp. 1201-1206 (1993).
Imai et al., Intern. Med., 38(10): pp. 829-832 (1999).
Kim et al., J. Chromatog., 738: p. 93 (2000).
Kovacs et al., “New Type of Bridged Monoamino-β-Cyclodextrins”, J. of Inclusion Phenomena and Molecular Recognition in Chemistry, 25: pp. 53-56 (1996).
Lavrijsen et al., Lancet, 340: pp. 251-252 (1992).
Neuvonen et al., Clin. Pharmacol. Therap., 60: pp. 54-61 (1996).
Nomeir et al., Antimicrob. Ag. Chemother., 44: p. 727 (2000).
Odds, F.C., J. Antimicrob. Chemother., 24: p. 533 (1989).
Sakesena et al., Anti-Infectives: Recent Advances in Chemistry and Structure Activity Relationships (Royal Soc. Chem., Cabridge), pp. 180-199 (1997).
Tetrahedron Letters, 37: p. 5657 (1996).
Tetrahedron Letters, 43(18): pp. 3359-3363 (2002).
Van Cutsem et al., Antimicrob. Ag. Chemother., 33: p. 2063 (1989).
Villa et al., Rev. Inst. Med. Trop., Sao Paulo, pp. 231-234 (Jul.-Aug. 2000).
Physician's Desk Reference, 56th ed., pp. 1800-1804 (2002).
Almarsson Orn
MacPhee Michael
Morissette Sherry Lynn
Peterson Matthew Lynn
Remenar Jules
Burgess Paul
McKenzie Thomas C.
Olson Christopher
TransForm Pharmaceuticals, Inc.
LandOfFree
CIS-itraconazole crystalline forms and related processes,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CIS-itraconazole crystalline forms and related processes,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CIS-itraconazole crystalline forms and related processes,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584935